Objective,2,To systematically evaluate the efficacy and safety of Dachengqi Decoction （DCQD） combined with octreotide and conventional therapy in the treatment of early postoperative inflammatory small bowel obstruction （EPISBO）.,Methods,2,Clinical randomized controlled trials （RCTs） that observed the effectiveness and safety of DCQD plus octreotide and conventional therapy in treating EPISBO with octreotide plus conventional therapy as the control were retrieved by searching the following databases as China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform （WanFang Data） and VIP Chinese Journal Service Platform （VIP）， etc. The collected RCTs were published between the dates of database establishment and August 5， 2022. The Cochrane systematic review manual was used to evaluate the methodological quality of the included RCTs and extract relevant data， and RevMan 5.4 was used to perform a meta-analysis of the extracted data.,Results,2,The included 6 articles involved 624 cases. The meta-analysis showed that the total effective rate of DCQD plus octreotide and conventional therapy for EPISBO was higher than that of octreotide plus conventional therapy ［,OR,=7.16，95%,CI,=（3.32，15.44）］， and DCQD plus octreotide and conventional therapy could better relieve abdominal pain and bloating ［,MD,=-1.81，95%,CI,=（-2.71，-0.92）］， facilitate anal gas evacuation ［,MD,=-0.95，95%,CI,=（-1.21， -0.69）］ and defecation ［,MD,=-0.62，95%,CI,=（-0.95，-0.29）］， and shorten the time course of symptom disappearance ［,MD,=-1.55，95%,CI,=（-2.70， -0.40）］， with a statistically significant difference （,P,<,0.01）. DCQD plus octreotide and conventional therapy had no significant advantage in lowering levels of tumor necrosis factor-α （TNF-α） ［,MD,=-3.87，95% ,CI,=（-8.32，0.58）］， hypersensitive C-reactive protein （hs-CRP） ［,MD,=-4.11，95% ,CI,=（-8.90，0.69）］， interleukin-6 （IL-6） ［,MD,=-41.86，95%,CI,=（-107.38，23.65）］， and the incidence of adverse reactions ［,MD,=0.91， 95%,CI,=（0.40，2.07）］ （,P,>,0.05）.,Conclusion,2,DCQD plus octreotide and conventional therapy has quite good efficacy in the treatment of EPISBO， but the conclusion needs to be validated by studies of higher quality due to the low quantity and quality of included literature.